BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets open in 2 hrs 29 mins

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
284.75-2.88 (-1.00%)
At close: 4:00PM EST
People also watch
CELGGILDREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close287.63
Open287.75
Bid280.56 x 200
Ask284.46 x 100
Day's Range283.41 - 288.11
52 Week Range223.02 - 333.65
Volume1,329,994
Avg. Volume1,790,527
Market Cap61.49B
Beta0.50
PE Ratio (TTM)16.82
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here's Why Celgene's Latest Drug Is So Exciting
    Motley Fool23 hours ago

    Here's Why Celgene's Latest Drug Is So Exciting

    The potential for ozanimod to reshape multiple sclerosis may be worth billions of dollars in annual sales.

  • Did Biogen Inc. Shoot Itself in the Foot?
    Motley Fool2 days ago

    Did Biogen Inc. Shoot Itself in the Foot?

    Biogen's list price for a new rare-disease drug makes it one of the world's most expensive. Was that a mistake?

  • American City Business Journals3 days ago

    ​Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A

    The head of the pharmaceutical industry’s biggest Washington lobby group visited Boston on Tuesday as part of a public relations campaign aimed at countering criticism of high drug prices — and singled out Cambridge-based Biogen for praise. During a question-and-answer session with reporters Tuesday, Stephen Ubl, the head of the Pharmaceutical Research and Manufacturers of America, spoke out against what he called a handful of “bad actors” — companies that purchase off-patent medicines that lack generic competition and then significantly raise the price. As an example, he pointed to Biogen’s (BIIB) Spinraza, which in December became the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants.